+

NO20032254L - Forbindelser for inhibering av ekspresjon av VACM-I - Google Patents

Forbindelser for inhibering av ekspresjon av VACM-I

Info

Publication number
NO20032254L
NO20032254L NO20032254A NO20032254A NO20032254L NO 20032254 L NO20032254 L NO 20032254L NO 20032254 A NO20032254 A NO 20032254A NO 20032254 A NO20032254 A NO 20032254A NO 20032254 L NO20032254 L NO 20032254L
Authority
NO
Norway
Prior art keywords
inhibition
expression
vacm
compounds
vcam
Prior art date
Application number
NO20032254A
Other languages
English (en)
Other versions
NO20032254D0 (no
NO319855B1 (no
Inventor
Russel M Medford
Patricia K Somers
Lee K Hoong
Charles Q Meng
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20032254L publication Critical patent/NO20032254L/no
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Publication of NO20032254D0 publication Critical patent/NO20032254D0/no
Publication of NO319855B1 publication Critical patent/NO319855B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20032254A 1997-05-14 2003-05-19 Anvendelse av forbindelser for fremstilling av medikament for inhibering av ekspresjon av VCAM-1. NO319855B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4702097P 1997-05-14 1997-05-14
PCT/US1998/009781 WO1998051662A2 (en) 1997-05-14 1998-05-14 Compounds and methods for the inhibition of the expression of vcam-1

Publications (3)

Publication Number Publication Date
NO20032254L true NO20032254L (no) 2000-01-10
NO20032254D0 NO20032254D0 (no) 2003-05-19
NO319855B1 NO319855B1 (no) 2005-09-26

Family

ID=21946634

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19995544A NO316221B1 (no) 1997-05-14 1999-11-12 Forbindelser for inhibering av ekspresjon av VCAM-1, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstillingav medikamentet
NO19995543A NO327603B1 (no) 1997-05-14 1999-11-12 Anvendelse av monoestere av probukol for fremstilling av medikamenter for behandling av kardiovaskulaer sykdom og inflammasjonssykdom
NO20032254A NO319855B1 (no) 1997-05-14 2003-05-19 Anvendelse av forbindelser for fremstilling av medikament for inhibering av ekspresjon av VCAM-1.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO19995544A NO316221B1 (no) 1997-05-14 1999-11-12 Forbindelser for inhibering av ekspresjon av VCAM-1, farmasöytisk sammensetning innbefattende samme og anvendelse av samme for fremstillingav medikamentet
NO19995543A NO327603B1 (no) 1997-05-14 1999-11-12 Anvendelse av monoestere av probukol for fremstilling av medikamenter for behandling av kardiovaskulaer sykdom og inflammasjonssykdom

Country Status (25)

Country Link
US (9) US6121319A (no)
EP (2) EP0994853B1 (no)
JP (4) JP2001524986A (no)
KR (5) KR100953990B1 (no)
CN (7) CN1287783C (no)
AT (3) ATE304350T1 (no)
AU (2) AU750041B2 (no)
BR (2) BR9809819A (no)
CA (3) CA2428130A1 (no)
CY (1) CY1107645T1 (no)
CZ (4) CZ301313B6 (no)
DE (3) DE69837295T2 (no)
DK (2) DK0981343T3 (no)
EA (5) EA010183B1 (no)
ES (3) ES2241139T3 (no)
HU (2) HUP0004592A3 (no)
ID (2) ID23877A (no)
IL (7) IL132798A0 (no)
NO (3) NO316221B1 (no)
NZ (2) NZ501069A (no)
PL (2) PL207885B1 (no)
PT (1) PT1464639E (no)
SK (4) SK285695B6 (no)
TR (2) TR199902803T2 (no)
WO (2) WO1998051662A2 (no)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501069A (en) * 1997-05-14 2000-07-28 Atherogenics Inc Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
EP1019034A2 (en) 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1017375A2 (en) 1997-09-24 2000-07-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US7361684B2 (en) * 1999-06-28 2008-04-22 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
AU2001247651B2 (en) * 2000-03-21 2007-01-04 Atherogenics, Inc Thioketals and thioethers for inhibiting the expression of vcam-1
EP1272465A2 (en) * 2000-04-11 2003-01-08 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US6323359B1 (en) * 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
MXPA02012660A (es) * 2000-06-20 2004-05-14 Atherogenics Inc 1,3-(fenilo-substituido-bis)-2-propen-1-onas y su uso para el tratamiento de padecimientos transmitidos por el vcam-1.
AUPQ872800A0 (en) * 2000-07-12 2000-08-03 Heart Research Institute, The Compositions and methods for treating cardiovascular disorders
AU2002248910A1 (en) 2000-11-17 2002-05-27 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrmidines
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
TWI337076B (en) 2001-01-26 2011-02-11 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR033855A1 (es) 2001-01-26 2004-01-07 Schering Corp Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes
JP4334233B2 (ja) * 2001-04-11 2009-09-30 アセロジエニクス・インコーポレイテツド プロブコールモノエステルによって血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌの機能性を改善するための方法
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
PT1429756E (pt) 2001-09-21 2007-01-31 Schering Corp Tratamento de xantoma com derivados de azetidinona como inibidores de absorção de esteróis
CN100415227C (zh) * 2001-10-25 2008-09-03 阿特罗吉尼克斯公司 化合物在制备用于治疗移植排斥的药物中的应用
KR20050044352A (ko) * 2001-11-09 2005-05-12 아테로제닉스, 인코포레이티드 심혈관 병리의 역전 및 예방 방법
HUP0500165A2 (en) 2001-12-19 2006-09-28 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
ITMI20020597A1 (it) * 2002-03-22 2003-09-22 Nicox Sa Derivati del probucolo
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
CA2492433A1 (en) * 2002-07-12 2004-01-22 Artherogenics, Inc. Organic amine salts of poorly soluble probucol esters and ethers
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
WO2004024094A2 (en) * 2002-09-13 2004-03-25 Samford University Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
WO2004032716A2 (en) * 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
AU2004204824B2 (en) * 2003-01-13 2010-12-23 Salutria Pharmaceuticals Llc Process of preparing esters and ethers of probucol and derivatives thereof
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009503A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
AU2004222434B2 (en) * 2003-03-17 2010-06-03 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
US7173129B2 (en) 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
WO2005025492A2 (en) * 2003-07-07 2005-03-24 Emory University Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
JP2007509054A (ja) * 2003-10-17 2007-04-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 血管健康を促進するシリルフェノール
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
DK1689706T3 (da) * 2003-11-14 2017-04-03 Temple Univ - Of The Commonwealth System Of Higher Education Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser
JP2007512262A (ja) * 2003-11-25 2007-05-17 ノボ　ノルディスク　アクティーゼルスカブ 肥満症の治療のための新規な化合物
US20060025481A1 (en) * 2004-02-09 2006-02-02 Strange Matthew L Process for preparation of probucol derivatives and polymorphic forms thereof
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
WO2005112914A2 (en) * 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20070260087A1 (en) * 2004-04-20 2007-11-08 Atherogenics, Inc. Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
EP1768660A4 (en) * 2004-07-01 2009-05-13 Atherogenics Inc COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP1844009A4 (en) * 2004-12-17 2010-04-21 Roland O Stocker COMPOSITIONS AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
BRPI0610602A2 (pt) 2005-04-21 2010-07-06 Atherogenics Inc processo para a separação de derivados de probucol
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
MX2008009354A (es) 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
AU2008230861A1 (en) 2007-03-26 2008-10-02 Salutria Pharmaceuticals, Llc Methods and compositions of derivatives of probucol for the treatment of diabetes
US20080280985A1 (en) * 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
WO2008130718A1 (en) 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
US20100324328A1 (en) * 2007-06-26 2010-12-23 Astrazeneca Ab Process For Isolating Mono-Carboxy Substituted Probucol Derivatives
EP2170847A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
NZ582249A (en) * 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
CN101868273B (zh) 2007-10-02 2014-10-15 莱蒙德尔有限公司 外部药泵
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
US8907095B2 (en) 2007-10-22 2014-12-09 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119
JP5669729B2 (ja) * 2008-05-13 2015-02-12 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダＧｅｎｍｅｄｉｃａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓｌ 代謝性障害を治療するのに有用なサリチレートコンジュゲート
WO2009143049A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
JP2011528365A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
US20100145305A1 (en) * 2008-11-10 2010-06-10 Ruth Alon Low volume accurate injector
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8722882B2 (en) 2008-12-23 2014-05-13 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8410122B2 (en) 2008-12-23 2013-04-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
US8152779B2 (en) * 2008-12-30 2012-04-10 Medimop Medical Projects Ltd. Needle assembly for drug pump
BRPI1013878A2 (pt) * 2009-03-16 2016-04-05 Genmedica Therapeutics Sl método para tratar distúrbios metabólicos, e, composto
CA2755072A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
CA2754509C (en) 2009-03-18 2018-03-06 Resverlogix Corp. Novel anti-inflammatory agents
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
CN104447936A (zh) 2009-05-18 2015-03-25 Ta科学公司(美国) 用于增加端粒酶活性的组合物和方法
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
US8157769B2 (en) * 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
EP2493307B1 (en) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
EP2503891B1 (en) 2009-11-23 2016-08-03 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
US9452261B2 (en) 2010-05-10 2016-09-27 Medimop Medical Projects Ltd. Low volume accurate injector
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
SG10201706858XA (en) 2013-02-28 2017-09-28 Harvard College Methods and compositions for mobilizing stem cells
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
EP3302652B1 (en) 2015-06-04 2023-09-06 Medimop Medical Projects Ltd. Cartridge insertion for drug delivery device
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
US10086145B2 (en) 2015-09-22 2018-10-02 West Pharma Services Il, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US11318254B2 (en) 2015-10-09 2022-05-03 West Pharma. Services IL, Ltd. Injector needle cap remover
CN109310816B (zh) 2016-01-21 2020-04-21 西医药服务以色列有限公司 针插入和缩回机构
US11311674B2 (en) 2016-01-21 2022-04-26 West Pharma. Services IL, Ltd. Medicament delivery device comprising a visual indicator
CN111544704B (zh) 2016-01-21 2022-06-03 西医药服务以色列有限公司 自动注射器中的力牵制
US11389597B2 (en) 2016-03-16 2022-07-19 West Pharma. Services IL, Ltd. Staged telescopic screw assembly having different visual indicators
US10376647B2 (en) 2016-03-18 2019-08-13 West Pharma. Services IL, Ltd. Anti-rotation mechanism for telescopic screw assembly
EP4427776A3 (en) 2016-06-02 2025-02-12 West Pharma Services IL, Ltd Three position needle retraction
US9650332B1 (en) * 2016-06-16 2017-05-16 Yong Xu Prodrug of probucol and method for preparing the same
JP7059251B2 (ja) 2016-08-01 2022-04-25 ウェスト ファーマ サービシーズ イスラエル リミテッド ドアの半閉じを防止するスプリング
JP6869327B2 (ja) 2016-08-01 2021-05-12 ウェスト ファーマ サービシーズ イスラエル リミテッド 回転防止カートリッジ
CN106905208B (zh) * 2017-02-27 2018-09-07 江西瑞雅药业有限公司 普罗布考前药及其制备方法和药物组合物
CN113855913A (zh) 2017-05-30 2021-12-31 西部制药服务有限公司(以色列) 用于穿戴式注射器的模块化驱动机构
JP7402799B2 (ja) 2017-12-22 2023-12-21 ウェスト ファーマ サービシーズ イスラエル リミテッド サイズの異なるカートリッジを利用可能な注射器
CN108299263B (zh) 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 一种普罗布考衍生物及其制备方法与应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3179701A (en) * 1962-05-14 1965-04-20 Shell Oil Co (3, 5-dialkyl-4-hydroxyphenyl) (3, 5-dialkyl-4-hydroxybenzyl) sulfides
US4115590A (en) * 1964-02-26 1978-09-19 Ethyl Corporation Binuclear phenols for reducing plasma lipid levels
GB1136539A (en) * 1966-12-13 1968-12-11 Uniroyal Inc Phenolic sulphides
GB1199871A (en) * 1967-05-11 1970-07-22 Consolidation Coal Co Improvements in or relating to Sulfur-Containing Bisphenols
US3485843A (en) * 1967-05-11 1969-12-23 Dow Chemical Co Piperazine adducts of ketone mercaptoles
GB1148550A (en) * 1967-12-02 1969-04-16 Uniroyal Inc Substituted benzylphenyl sulfides and their use as antioxidants
US3479407A (en) * 1968-11-06 1969-11-18 Consolidation Coal Co Sulfurization of 2,6-di-tert-butylphenol
US3576883A (en) * 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
DE2104524C3 (de) 1970-09-16 1980-08-07 Veb Kombinat Umformtechnik Herbert Warnke Erfurt, Ddr 5000 Erfurt Hydraulische Überlastsicherung
FR2130975A5 (en) * 1971-03-29 1972-11-10 Aries Robert Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics
FR2133024A5 (en) * 1971-04-06 1972-11-24 Aries Robert Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity
FR2134810A5 (en) * 1971-04-21 1972-12-08 Aries Robert Bis-(3-alkyl-5-t-alkyl-4-(thiazole-5-carboxy)phenylthio) alcanes - - with hypocholesterolaemic and hypolipaemic activity
FR2140769A5 (en) * 1971-06-07 1973-01-19 Aries Robert Benzofuryloxy alkanoic derivs of probucol - hypocholesterolemic and hypolipemic agents
FR2140771A5 (en) * 1971-06-07 1973-01-19 Aries Robert Tetralinyl phenoxy alkanoic esters - of bis hydroxyphenylthio alkanes, hypolipemics etc
FR2168137A1 (en) * 1972-01-17 1973-08-31 Dynachim Sarl Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities
JPS4975552A (no) * 1972-11-20 1974-07-20
US3952064A (en) * 1973-03-12 1976-04-20 Crown Zellerbach Corporation Process for producing mercaptophenols
US4029812A (en) * 1976-02-18 1977-06-14 The Dow Chemical Company Novel hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thio carboxamides
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4968514A (en) * 1984-12-11 1990-11-06 Forbes Polytech, Inc. Beer bottle with fully reacted thermoplastic polyurethane crown capliner
AU584669B2 (en) * 1985-02-04 1989-06-01 G.D. Searle & Co. Novel disubstituted 4-hydroxyphenylthio anilides
US4679520A (en) 1985-06-10 1987-07-14 Harken Olaf T Mainsail reefing and furling device and method
DE3530256A1 (de) 1985-08-23 1987-02-26 Merrell Dow Pharma Verwendung von probucol bei der behandlung von herzarrhythmie
US4755524A (en) * 1986-01-31 1988-07-05 G. D. Searle & Co. Novel phenolic thioethers as inhibitors of 5-lipoxygenase
DE3625279A1 (de) 1986-07-25 1988-02-04 Merrell Dow Pharma Verwendung von probucol zur vorbeugung und behandlung von erkrankungen des herzens
US4975467A (en) 1987-03-17 1990-12-04 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
EP0292660B1 (en) * 1987-03-17 1992-03-18 Merrell Dow Pharmaceuticals Inc. Alkylidenedithiobis (substituted) phenols for inhibiting interleukin-1 release and for alleviating interleukin-1 mediated conditions
US4752616A (en) * 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use
US4968710A (en) 1987-11-13 1990-11-06 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
NZ226621A (en) * 1987-11-13 1991-12-23 Riker Laboratories Inc Di-tert butyl phenols substituted by alkoxy, benzyloxy, or benzylthio groups; pharmaceutical compositions containing them
US5066822A (en) 1987-11-13 1991-11-19 Riker Laboratories, Inc Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group
CH675422A5 (no) 1988-03-31 1990-09-28 Symphar Sa
JP2754039B2 (ja) 1988-06-24 1998-05-20 塩野義製薬株式会社 ジ―ｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
JP2627003B2 (ja) * 1989-01-25 1997-07-02 塩野義製薬株式会社 ジーｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
US5527945A (en) 1989-02-10 1996-06-18 Basf Aktiengesellschaft Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
JP3065636B2 (ja) * 1989-06-29 2000-07-17 塩野義製薬株式会社 ［ジ―ｔｅｒｔ―ブチル（ヒドロキシ）フェニルチオ］置換ヒドロキサム酸誘導体
CA2017956A1 (en) * 1989-07-06 1991-01-06 Werner Bollag Use of retinoids
DE3929913A1 (de) 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
US5115250A (en) * 1990-01-12 1992-05-19 Hewlett-Packard Company Wiper for ink-jet printhead
US5112870A (en) 1990-05-09 1992-05-12 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5061734A (en) 1990-05-09 1991-10-29 Merrell Dow Pharmaceuticals Inc. Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5085777A (en) * 1990-08-31 1992-02-04 E. I. Du Pont De Nemours And Company Reverse osmosis membranes of polyamideurethane
FR2666583B1 (fr) * 1990-09-06 1994-09-09 Adir Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
RU2024509C1 (ru) * 1991-05-07 1994-12-15 Всероссийский научный центр по безопасности биологически активных веществ Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность
GB9115951D0 (en) 1991-07-24 1991-09-11 Pfizer Ltd Indoles
EP0625138B1 (de) 1992-02-05 1999-06-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue amidinderivate, ihre herstellung und verwendung als arzneimittel mit ltb4-antagonistischer wirkung
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
US5310949A (en) 1992-09-02 1994-05-10 Merck & Co., Inc. Cholesterol lowering compounds
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5821260A (en) * 1992-10-30 1998-10-13 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5662934A (en) * 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
US5585235A (en) 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
FR2704224B1 (fr) * 1993-04-20 1995-08-25 Adir Nouveaux acides et esters phénoxy isobutyriques substitués.
JPH06312978A (ja) * 1993-04-30 1994-11-08 Japan Tobacco Inc ホスホリパーゼａ２阻害活性を有する新規フタルイミド誘導体
US5411741A (en) 1993-07-29 1995-05-02 Zaias; Nardo Method and composition for skin depigmentation
GB9320113D0 (en) 1993-09-29 1993-11-17 Zeneca Ltd Tricyclic derivatives
ATE324113T1 (de) * 1993-12-10 2006-05-15 Merrell Pharma Inc Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom
US5426196A (en) 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
JPH07328425A (ja) * 1994-06-03 1995-12-19 Toshiba Corp プラズマ化学反応装置
CA2153553A1 (en) 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
US5635514A (en) * 1994-10-25 1997-06-03 G. D. Searle & Company Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
US5792787A (en) * 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
JPH0959258A (ja) * 1995-08-11 1997-03-04 Ono Pharmaceut Co Ltd グアニジル誘導体
FR2738817B1 (fr) * 1995-09-14 1997-10-17 Adir Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1997015546A1 (fr) * 1995-10-26 1997-05-01 Nippon Shinyaku Co., Ltd. Derives d'acide carboxylique et compositions pharmaceutiques
DE69705819T2 (de) 1996-01-15 2002-04-11 Janssen Pharmaceutica N.V., Beerse Angiogenesis hemmende pyridazinamine
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
IL129957A (en) * 1996-11-20 2005-06-19 Aventis Pharma Inc Substituted phenols and phenyl esters and pharmaceutical compositions containing them
WO1998030255A2 (en) 1997-01-09 1998-07-16 Localmed, Inc. Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels
GB9705502D0 (en) 1997-03-17 1997-05-07 Univ Wales Swansea The Chlorination or aromatic compounds and catalysts therefor
AU6715098A (en) 1997-03-24 1998-10-20 Gilles Cote Vascular remodeling agent
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
NZ501069A (en) * 1997-05-14 2000-07-28 Atherogenics Inc Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1017375A2 (en) 1997-09-24 2000-07-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
WO1999024400A1 (en) 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
DE19850532A1 (de) 1998-11-03 2000-05-04 Nematel Dr Rudolf Eidenschink Bisphenylthio-Verbindungen
JP2002529740A (ja) * 1998-11-09 2002-09-10 アセロジエニクス・インコーポレイテツド 血漿コレステロールレベルを低下させるための方法及び組成物
ES2198980T3 (es) 1998-11-23 2004-02-01 Janssen Pharmaceutica N.V. Derivados de 6-azauralico inhibidores de il-5.
KR100870508B1 (ko) 1999-03-10 2008-11-25 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 지방 유래 간세포 및 격자
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AU2001247651B2 (en) * 2000-03-21 2007-01-04 Atherogenics, Inc Thioketals and thioethers for inhibiting the expression of vcam-1
EP1282445A2 (en) 2000-03-21 2003-02-12 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
US6323359B1 (en) 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
JP4334233B2 (ja) * 2001-04-11 2009-09-30 アセロジエニクス・インコーポレイテツド プロブコールモノエステルによって血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌの機能性を改善するための方法
CN1209392C (zh) 2001-05-14 2005-07-06 阿姆诺洼化学有限公司 由含侧氟碳基的环状单体得到的聚合物表面活性剂
US7187870B2 (en) * 2003-10-15 2007-03-06 Oewaves, Inc. Tunable balanced opto-electronic filters and applications in opto-electronic oscillators

Also Published As

Publication number Publication date
PL343904A1 (en) 2001-09-10
HUP0004230A3 (en) 2001-12-28
KR100919883B1 (ko) 2009-09-30
US6147250A (en) 2000-11-14
DE69831566T2 (de) 2006-06-14
US7189870B2 (en) 2007-03-13
US6602914B2 (en) 2003-08-05
CN1263462A (zh) 2000-08-16
SK153199A3 (en) 2000-05-16
KR100953990B1 (ko) 2010-04-21
NO995543L (no) 2000-01-10
EA200601059A1 (ru) 2007-02-27
TR199902802T2 (xx) 2000-04-21
HU226611B1 (en) 2009-04-28
CY1107645T1 (el) 2013-04-18
CA2289851A1 (en) 1998-11-19
EP0994853B1 (en) 2005-04-27
SK153299A3 (en) 2000-05-16
KR20080066885A (ko) 2008-07-16
NZ528906A (en) 2005-06-24
US20020188118A1 (en) 2002-12-12
TR199902803T2 (xx) 2000-07-21
CA2428130A1 (en) 1998-11-19
CZ301183B6 (cs) 2009-12-02
EA199901027A1 (ru) 2000-06-26
DE69837295T2 (de) 2007-11-15
US20020177717A1 (en) 2002-11-28
KR20010012503A (ko) 2001-02-15
PL194329B1 (pl) 2007-05-31
CA2292388C (en) 2004-07-20
IL164568A (en) 2010-05-31
NO20032254D0 (no) 2003-05-19
PT1464639E (pt) 2007-06-15
EA010183B1 (ru) 2008-06-30
ATE356113T1 (de) 2007-03-15
ATE304350T1 (de) 2005-09-15
JP2006265257A (ja) 2006-10-05
PL207885B1 (pl) 2011-02-28
ATE294158T1 (de) 2005-05-15
HK1025947A1 (en) 2000-12-01
US20020169215A1 (en) 2002-11-14
US20020193446A1 (en) 2002-12-19
ID23877A (id) 2000-05-25
EP0994853A2 (en) 2000-04-26
AU7485198A (en) 1998-12-08
CZ301302B6 (cs) 2010-01-06
SK286392B6 (sk) 2008-09-05
AU750041B2 (en) 2002-07-11
KR20070008725A (ko) 2007-01-17
AU747801B2 (en) 2002-05-23
CN1287783C (zh) 2006-12-06
CN1496739A (zh) 2004-05-19
JP3930056B2 (ja) 2007-06-13
IL132798A0 (en) 2001-03-19
DK0981343T3 (da) 2006-01-30
PL336788A1 (en) 2000-07-17
US6617352B2 (en) 2003-09-09
CN100453530C (zh) 2009-01-21
JP2001524986A (ja) 2001-12-04
EA199901026A1 (ru) 2000-08-28
ES2248901T3 (es) 2006-03-16
CN1977837B (zh) 2010-12-08
IL132797A0 (en) 2001-03-19
DE69829966T2 (de) 2006-02-09
CN101284808A (zh) 2008-10-15
SK286766B6 (sk) 2009-05-07
HUP0004592A2 (hu) 2001-06-28
NO327603B1 (no) 2009-08-31
NO995544L (no) 2000-01-10
SK286674B6 (sk) 2009-03-05
AU7571198A (en) 1998-12-08
EP0981343B1 (en) 2005-09-14
CN1977836A (zh) 2007-06-13
BR9809793A (pt) 2000-06-27
DE69837295D1 (de) 2007-04-19
ES2283933T3 (es) 2007-11-01
NZ501069A (en) 2000-07-28
BR9809819A (pt) 2001-09-18
CN1200704C (zh) 2005-05-11
CZ9904023A3 (cs) 2001-07-11
CZ9904024A3 (cs) 2001-10-17
ID29158A (id) 2001-08-02
EA009370B1 (ru) 2007-12-28
WO1998051662A3 (en) 2000-03-02
IL132798A (en) 2006-12-31
EA200500249A1 (ru) 2005-06-30
NO995543D0 (no) 1999-11-12
WO1998051662A2 (en) 1998-11-19
NO319855B1 (no) 2005-09-26
CN1263522A (zh) 2000-08-16
CN1977837A (zh) 2007-06-13
US6828447B2 (en) 2004-12-07
DK1464639T3 (da) 2007-07-09
KR20070007207A (ko) 2007-01-12
NO995544D0 (no) 1999-11-12
CZ301985B6 (cs) 2010-08-25
JP2002503227A (ja) 2002-01-29
CN1496740A (zh) 2004-05-19
EA012847B1 (ru) 2009-12-30
IL178072A (en) 2010-12-30
DE69831566D1 (de) 2006-01-26
IL164568A0 (en) 2005-12-18
ES2241139T3 (es) 2005-10-16
US6121319A (en) 2000-09-19
HUP0004230A2 (hu) 2001-06-28
WO1998051289A2 (en) 1998-11-19
AU747801C (en) 2003-01-30
HUP0004592A3 (en) 2001-12-28
NO316221B1 (no) 2003-12-29
KR20010012504A (ko) 2001-02-15
EA200800375A1 (ru) 2008-06-30
WO1998051289A3 (en) 1999-05-14
US20050090487A1 (en) 2005-04-28
CA2292388A1 (en) 1998-11-19
IL178072A0 (en) 2006-12-31
US6548699B1 (en) 2003-04-15
KR100882335B1 (ko) 2009-02-11
SK285695B6 (sk) 2007-06-07
US20080214660A1 (en) 2008-09-04
EA009987B1 (ru) 2008-04-28
IL175130A (en) 2009-02-11
CN1275596C (zh) 2006-09-20
JP2006232848A (ja) 2006-09-07
US7375252B2 (en) 2008-05-20
CA2289851C (en) 2009-03-10
EP0981343A2 (en) 2000-03-01
DE69829966D1 (de) 2005-06-02
HK1024629A1 (en) 2000-10-20
CZ301313B6 (cs) 2010-01-13

Similar Documents

Publication Publication Date Title
NO20032254L (no) Forbindelser for inhibering av ekspresjon av VACM-I
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
PT828736E (pt) Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase
NO20034056D0 (no) Proliferative sykdommer
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
NO20005548D0 (no) Mykobakterieinhibitorer
EP1468989A3 (en) Compounds and methods for the inhibition of the expression of VCAM-1
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
MX9704739A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados.
ATE111469T1 (de) Pyrimido-benzothiazine mit lipoxygenase-hemmung.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载